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Abstract
Background: Germline inactivating mutations in BRCA1 and BRCA2 underlie a major proportion
of the inherited predisposition to breast and ovarian cancer. These mutations are usually detected
by DNA sequencing. Cost-effective and rapid methods to screen for these mutations would enable
the extension of mutation testing to a broader population. High resolution melting (HRM) analysis
is a rapid screening methodology with very low false negative rates. We therefore evaluated the
use of HRM as a mutation scanning tool using, as a proof of principle, the three recurrent BRCA1
and BRCA2 founder mutations in the Ashkenazi Jewish population in addition to other mutations
that occur in the same regions.
Methods: We designed PCR amplicons for HRM scanning of BRCA1 exons 2 and 20 (carrying the
founder mutations185delAG and 5382insC respectively) and the part of the BRCA2  exon 11
carrying the 6174delT founder mutation. The analysis was performed on an HRM-enabled real time
PCR machine.
Results: We tested DNA from the peripheral blood of 29 individuals heterozygous for known
mutations. All the Ashkenazi founder mutations were readily identified. Other mutations in each
region that were also readily detected included the recently identified Greek founder mutation
5331G>A in exon 20 of BRCA1. Each mutation had a reproducible melting profile.
Conclusion: HRM is a simple and rapid scanning method for known and unknown BRCA1 and
BRCA2 germline mutations that can dramatically reduce the amount of sequencing required and
reduce the turnaround time for mutation screening and testing. In some cases, such as tracking
mutations through pedigrees, sequencing may only be necessary to confirm positive results. This
methodology will allow for the economical screening of founder mutations not only in people of
Ashkenazi Jewish ancestry but also in other populations with founder mutations such as Central
and Eastern Europeans (BRCA1 5382insC) and Greek Europeans (BRCA1 5331G>A).
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Background
BRCA1 and BRCA2 are the two most frequently mutated
genes underlying inherited breast and ovarian cancer. As
both are large multi-exon genes, with inactivating muta-
tions occurring across the entire coding region, the conse-
quent cost of BRCA1/2 mutation screening has limited
mutation testing to those who are most likely to have a
mutation based on their family history of cancer. Conse-
quently, a significant proportion of women carrying
germline mutations are missing out on the opportunity to
have mutation screening and thereby to modify their risk
of breast cancer, particularly those with a small pedigree
structure or where the inheritance is through the paternal
lineage. The costs of full sequencing are reducing, but it
will be some years before they drop significantly enough
to have a serious impact on the numbers of genetic tests
provided by scarce health dollars. In the meantime, an
alternative approach is to use a mutation scanning tech-
nique to highlight variations in genomic sequences which
are then characterised by sequencing.
High resolution melting (HRM) is a new methodology for
mutation scanning in which the mutation scanning is car-
ried out in the same tube or well in which the sequence is
amplified (reviewed in [1]). The PCR reactions and HRM
can all be performed in a single run of less than 2 hours
resulting in extremely rapid screening. Up to 384 scans
(generally 192 samples in duplicate) can be done at the
same time enabling very high throughput.
We selected several regions of the BRCA1  and  BRCA2
genes known to carry a number of founder mutations in
order to investigate the ability of HRM for reliable detec-
tion of both known founder mutations and other muta-
tions occurring in close proximity to those founder
mutations. Founder mutations are specific mutations
found at high frequency in a particular population as a
result of geographic, cultural or ethnic isolation. Individ-
uals of Ashkenazi Jewish ancestry have a particularly high
carrier rate for three mutations predisposing to the hered-
itary breast and ovarian cancer syndrome: the 185delAG
and the 5382insC in BRCA1 and the 6174delT in BRCA2
with a population prevalence of approximately 2.5% [2-
4]. The 5382insC in exon 20 of BRCA1 is also one of the
most common recurrent mutations in Central and Eastern
Europeans [5-9]. This exon also contains the 5331G>A
BRCA1 mutation recently shown to be a founder muta-
tion in Greek Europeans [10].
Methods
Samples
Samples from 29 carriers of known mutations in one of
the regions of the BRCA1 and BRCA2 genes that contain
the Ashkenazi founder mutations were obtained from
existing samples in the Diagnostic Molecular Pathology
laboratory at the Peter MacCallum Cancer Centre. Up to
five biological replicate samples (i.e separate individuals)
were chosen for each mutation. The study was performed
under guidelines approved by the Peter MacCallum Ethics
of Human Research Committee (approval 03/90).
HRM Assay Conditions
Effective primer design is an important component of
HRM analysis. Primers were designed to flank the coding
regions of BRCA1 exons 2 and 20 and to amplify a 534 bp
region surrounding the 6174delT mutation on BRCA2
exon 11. All amplicons were chosen so that they con-
tained a single melting domain using the Poland program
[11]. It was also necessary to ensure that the primers did
not overlay known single nucleotide polymorphisms
(SNPs) that may lead to single alleles not being amplified.
An example of this was previously reported for the
6174delT mutation where the wild type allele was not
amplified[12]. In other cases, this would lead to lack of
amplification of the mutant allele. The primers were
designed to be annealed at 60°C using Primer Express
software (Applied Biosystems, Foster City, CA) to calcu-
late the "Tm". Primer sequences are listed in Table 1.
PCR and HRM Assay Conditions
The PCR and HRM were performed in a single run on a
LightCycler 480 (Roche Diagnostics, Penzberg, Germany)
in a reaction mix containing 2.5 µl (25 ng) of genomic
DNA, either 400 nM (exon 2 and exon 11) or 200 nM
(exon 20) of each primer and 3 mM MgCl2 in the LightCy-
cler®  480 High Resolution Melting Master containing
Table 1: List of primers used to amplify BRCA1 exon 2, BRCA1 exon 20 and part of BRCA2 exon11.
Gene Sequence
BRCA1 Forward primer 5'-AAAAGATATAGATGTATGTTTTGCTAATGTGT-3'
exon 2 Reverse primer 5'-TCCCAAATTAATACACTCTTGTGCTGA-3'
BRCA1 Forward primer 5'-GAGTGGTGGGGTGAGATTTTTGTC-3'
exon 20 Reverse primer 5'-CCTGATGGGTTGTGTTTGGTTTCT-3'
BRCA2 Forward primer 5'-CGAAAATTATGGCAGGTTGTTACG-3'
exon 11 Reverse primer 5'-GCTTTCCACTTGCTGTACTAAATCCA-3'BMC Cancer 2008, 8:59 http://www.biomedcentral.com/1471-2407/8/59
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ResoLight dye (Roche Diagnostics) with PCR grade water
adjusted to a total volume of 10 µl. The reaction condition
included an activation step at 95°C for 10 minutes fol-
lowed by 55 cycles of 95°C for 10 seconds, a touch down
of 65°C to 55°C for 10 seconds (1°C/cycle) and 72°C for
30 seconds. Before the high resolution melting step the
products were heated to 95°C for 1 minute. The HRM was
carried out over the range from 72°C to 95°C rising at
1°C per second with 30 acquisitions per degree. All reac-
tions were performed in duplicate in a 96-well microtiter
plate.
HRM Analysis
Upon completion of the run (approximately 2 hours),
HRM curve analysis was performed using the LightCycler
480 Software version 1.3. supplied with the LightCycler
480. The melting curves were normalised and temperature
shifted to allow samples to be directly compared. Differ-
ence plots were generated by selecting a negative control,
converting the melting profile to a horizontal line and
normalising the melting profiles of the other samples
against this sample Significant differences in fluorescence
from the horizontal baseline were indicative of muta-
tions. Differences were judged as significant if the repli-
cates fell outside the range of variation seen in the wild
type samples.
Results
We tested DNA from the peripheral blood of individuals
heterozygous for known mutations in the three regions
containing the Ashkenazi founder mutations predispos-
ing to breast and ovarian cancer as well a series of wild
type controls (Table 2). As in our previous publications on
mutation detection [13,14], we found that difference
curves, where the melting profile of one of the control
samples is converted to a horizontal line and the melting
profiles of the other samples are normalised against this
line, allowed the best visualisation of mutations.
For BRCA1 exon 2 (Figure 1a), we tested DNA from 4 indi-
viduals with the Ashkenazi mutation 185delAG as well as
1 individual with the mutation 188del11 and 2 individu-
als with the mutation 185insA. The mutations were all
readily differentiated from the wild type. They were also
readily differentiated from each other giving characteristic
melting curves as is readily seen from the figure. It can also
readily be seen that biological replicates had near identi-
cal melting patterns.
Similarly for the amplicon including BRCA1 exon 20 (Fig-
ure 1b) and for the amplicon including the region around
the 6174delT mutation in BRCA2 exon 11 (Figure 1c), all
the mutations were readily identified, displayed character-
istic melting curves and were clearly differentiated from
the wild type and from each other. The mutations tested
in addition to the 5382insC (6 individuals) were the
5396+1G>A (4 individuals) and the 5331G>A (5 individ-
uals). The mutations tested in addition to the 6174delT (3
individuals) were the 6024delTA (2 individuals) and the
6293C>G (2 individuals). Biological replicates again had
near identical melting patterns.
Discussion
DNA sequencing is regarded as the gold standard for
BRCA1 and BRCA2 mutation detection. However, in prac-
tice, most testing laboratories perform a preliminary scan
of exons and splice junctions using methods such as the
protein truncation test (PTT), denaturing gradient gel elec-
trophoresis (DGGE) and/or denaturing high pressure liq-
uid chromatography (DHPLC) to reduce cost and increase
throughput. Any region that is found to potentially con-
tain a mutation by scanning is then characterised by
sequencing.
Scanning methods are particularly relevant to studies
involving large numbers of individuals. A recent Cana-
dian study [15] used a combination of PTT, DGGE and
DHPLC to scan the BRCA1 and BRCA2 genes, followed by
DNA sequencing to screen for BRCA1 and BRCA2 muta-
tions. Although very sensitive, PTT, DGGE and DHPLC do
not detect all mutations. In particular, PTT, which is used
for screening of the large exons comprising approximately
half of the total sequence of the BRCA1 and BRCA2 genes,
does not detect missense alterations. Both DHPLC and
DGGE are both operator and interpreter sensitive. It has
been shown that DHPLC, which is currently considered as
the gold standard of screening methods, is superior to
DGGE for the detection of BRCA1 and BRCA2 mutations
[16].
Table 2: List of mutations tested
BRCA1 exon 2 BRCA1 exon 20 BRCA2 exon 11
Mutation Number of samples Mutation Number of samples Mutation Number of samples
Wild type 13 Wild type 16 Wild type 26
188del11 1 5396+1G>A 4 6174delT 3
185delAG 4 5382insC 6 6293C>G 2
185insA 2 5331G>A 5 6024delTA 2BMC Cancer 2008, 8:59 http://www.biomedcentral.com/1471-2407/8/59
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Difference plot showing different mutations relative to the wild type controls Figure 1
Difference plot showing different mutations relative to the wild type controls. In difference plots, the melting profile 
of a wild type control is chosen as a horizontal base line and the relative differences in the melting of all the other samples are 
plotted relative to this baseline. The figure shows difference plots for each of the 3 exons containing one of the common 
Ashkenazi mutations (185delAG, 5382insC and 6174delT). Each trace represents the amplicon from a different individual's 
DNA sample. All mutations were clearly distinct from the wild type controls. a. BRCA1 exon 2: Melt curves of each mutation 
(pink: 188del11, red: 185delAG and green: 185insA) were plotted against the wild type (blue). b. BRCA1 exon 20: Melt curves 
of each mutation (pink: 5396+1G>A, red: 5331G>A and green: 5382insC) were plotted against melt curve of the wild type 
(blue). c. BRCA2 exon 11: Melt curves of each mutation (pink: 6024delTA, red: 6293C>G and green: 6174delT) were plotted 
against melt curve of the wild type (blue).BMC Cancer 2008, 8:59 http://www.biomedcentral.com/1471-2407/8/59
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HRM is an in-well scanning method in which the melting
analysis is performed immediately after the PCR amplifi-
cation and is thus particularly suitable for high-through-
put applications. HRM is predicted to have close to a
100% sensitivity as each heterozygous mutation should
create a readily detected heteroduplex [17]. Heterozygotes
are readily recognisable by HRM because they form a pro-
portion of heteroduplexes which melt differently to per-
fectly matched homoduplexes. The use of HRM to detect
both known and novel germline mutations has been
reported for several other genes including the EXT1, EXT2,
RET, GJB1 and CFTR genes [18-21]. All germline muta-
tions in the BRCA1  and  BRCA2  genes are expected to
occur in heterozygotes as mutant homozygotes are lethal
[22] and consistent with this, none have been reported.
A comparative study has recently shown that the sensitiv-
ity and specificity of HRM is better than DHPLC which is
the current gold standard of scanning methods [17]. In
addition, HRM is more rapid as the melting analysis is
performed in all wells simultaneously whereas DHPLC
involves the removal of the PCR product (in itself prob-
lematical because of the PCR contamination issue) and
then the sequential analysis of each sample. The instru-
mentation for DHPLC is more expensive and the analysis
generates chemical waste which requires disposal. There
are therefore significant time and cost advantages in
adopting HRM.
In our hands, all the different mutations in the 3 regions
that we analysed from the BRCA1 and BRCA2 genes were
detected, giving us a sensitivity of 100% in this pilot
study. The true sensitivity remains to be determined in a
larger study, but publications for other genes indicate that
it is likely to be very high [14,17]. A larger study is cur-
rently underway in our lab testing several hundred known
mutations in historic samples across all BRCA1  and
BRCA2 coding regions in combination with the screening
of prospectively collected diagnostic samples. This will
provide further insight into the true sensitivity of HRM
and applicability of the method for mutation scanning of
the entire coding regions of BRCA1 and BRCA2.
Currently, the three founder mutations associated with
Ashkenazi Jewish ancestry are generally identified using
sequencing and, once a mutation is identified in a family,
other family members can undergo predictive testing by
sequencing for the exon in which the mutation was iden-
tified. However, as the frequency of the three founder
mutations is relatively high, it is possible that a second
mutation might be segregating in the family and so ideally
all founder mutations should be sought in other family
members. HRM would allow testing for all three
Ashkenazi mutations in family members at relatively low
cost. The testing would also enable inexpensive popula-
tion-based screening of individuals with Jewish ancestry
for the founder mutations.
We also detected the 5331G>A mutation in BRCA1 exon
20 that has recently been shown to be a Greek founder
mutation [10]. Large scale screening for this founder
mutation can now be undertaken in relevant populations.
A similar approach can be applied to other founder muta-
tions in regions not screened for in this study. The ability
to detect mutations by HRM alone has implications for
economical large scale population screening studies to
understand the prevalence and characteristics of other
known or suspected founder mutations.
HRM can also be used as an inexpensive methodology for
tracking mutations across pedigrees. Each mutation had a
characteristic melting profile that would allow it to be
identified by using a control for that mutation. In some
cases, this would remove the necessity for sequencing.
However, for diagnostic purposes, any apparently muta-
tion positive individual should be confirmed by sequenc-
ing as different mutations can also have similar profiles.
Dufresne and colleagues [23] reported the use of melt
curve analysis for the specific detection of the Ashkenazi
mutations using SYBR Green 1 incorporation as moni-
tored by a standard real time PCR machine. This approach
is melting analysis rather then the high resolution melting
(HRM) we have used here. Whereas their methodology is
capable of detecting known mutations such as the
Ashkenazi mutations by designing primers flanking those
mutations, our methodology is an essentially different
and more powerful methodology which is designed pri-
marily as a screening methodology. We used an appropri-
ate dye for high resolution melting, an HRM enabled real
time PCR machine (only recently available) and software
that allows HRM analysis to be performed. The greater
sensitivity of HRM allowed longer amplicons to be used
(534 base pairs was successfully used for the region sur-
rounding the 6174delT mutation) which allows for the
screening of unknown mutations as we have demon-
strated. Thus by examining extra, non-founder mutations
in close proximity to the founder mutations we show that
this method easily detects missense mutations as well as
small insertions and deletions. Interestingly, the missense
mutation heterozygotes melt earlier than some of the
deletion/insertion heterozygotes; the 6174delT initially
being more stable than even the wildtype.
Based on our current findings, we are confident that HRM
for mutation detection will prove superior to the current
germline mutation screening approaches in terms of
speed, and cost and give at least equivalent sensitivity.
HRM is the most rapid of the current screening methods
as the only set-up involved is the PCR amplification, up toBMC Cancer 2008, 8:59 http://www.biomedcentral.com/1471-2407/8/59
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384 reactions can be tested in the one run for a given
amplicon and the results can be rapidly scanned by a tech-
nician. Consequently, HRM is the least expensive of the
current screening methods as the only consumables cost
involved is the PCR amplification with a HRM dye and the
reaction vessels while the rapid scanning reduces labour
costs. Consequently, we believe that HRM may become
the method of choice for BRCA1 and BRCA2 mutation
screening in both the diagnostic and research settings.
Conclusion
This study demonstrates the use of HRM as a method to
scan for the common germline BRCA1 and BRCA2 muta-
tions such as those seen in Ashkenazi Jewish individuals.
It also demonstrates the potential of this method for
screening the BRCA1 and BRCA2 genes as every mutation
tested for was readily detected. Whereas, the use of HRM
for full screening of the BRCA1 and BRCA2 still needs to
be verified by sequencing, screening for the Ashkenazi
founder mutations (or other founder mutations) can now
be carried out by laboratories with access to the increas-
ingly available high resolution melting platform. The
method is sensitive, rapid and cost effective and will
markedly reduce the amount of sequencing required in
mutational studies of BRCA1 and BRCA2, and thereby the
time and cost required for these studies.
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